Targeting Acute Bladder Infections (Cystitis)

This medicine is applied across domains where additional symptomatic support is needed, primarily for acute, uncomplicated lower urinary tract infections (cystitis) when the symptoms are caused by susceptible bacteria in the bladder. It is commonly used for treating uncomplicated cystitis in women and adolescent girls, where it provides support that contributes to the elimination of the microbial cause of the infection. The use is aligned with the goal of managing the underlying microbial imbalance, which may assist with maintaining functional stability in situations where symptoms may intensify temporarily.

Easing of Pain and Urgency Symptoms

This therapeutic domain addresses symptoms related to physical discomfort that interfere with daily functioning, which often characterize acute bladder infections. The medication may be applied to help ease challenging symptoms, specifically the burning or stinging sensation during urination (dysuria), and symptoms of increased neurological or muscular activity, like urinary frequency and urgency. Providing symptomatic relief contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes by easing distress.

Use Against Resistant Uropathogens

The primary therapeutic focus for this preparation is on localized, acute conditions presenting with symptomatic discomfort, such as acute bacterial cystitis and other forms of susceptible lower urinary tract infections. This therapeutic approach offers additional support in managing symptoms in conditions where functional stability becomes affected by infections, including those with strains such as Extended-Spectrum Beta-Lactamase (ESBL)-producing E. coli. The application of targeted agents is relevant when supportive symptom management is appropriate, particularly for patients facing recurrent or challenging uropathogens.

---

Quick Fact: Relief for Acute Urinary Discomfort

• Targeted Conditions: Acute, uncomplicated bacterial cystitis.
• Core Benefit: Contributes to the elimination of the microbial cause, helping manage the acute symptoms of painful and frequent urination.

• Clinical Relevance: Commonly used in situations involving symptoms related to inflammatory or irritative states in the lower urinary tract.

Regulatory References

1. European Medicines Agency (EMA) guidance on the oral formulation

Fosfomycin Esparma, which contains the active substance fosfomycin trometamol, is generally intended for the treatment of uncomplicated urinary tract infections (acute cystitis) in adult women and adolescent girls.

Fosfomycin is typically not indicated for the treatment of kidney infections (pyelonephritis) or complex urinary tract infections, and its use should be reserved for infections caused by susceptible bacteria, most commonly Escherichia coli and Enterococcus faecalis.

Contraindications and Precautions

There are specific situations and medical conditions where the use of this medication is contraindicated or requires caution:

Group/Condition	Status	Important Considerations
Hypersensitivity	Contraindicated	Known allergy to fosfomycin or any component of the formulation.
Severe Renal Insufficiency	Contraindicated	Patients with severe kidney impairment (creatinine clearance < 10 mL/min) or those undergoing hemodialysis.
Children	Not Generally Recommended	The oral granular form is generally not recommended for children under 12 years of age for uncomplicated UTIs.
Gastrointestinal	Use with Caution	A history of severe diarrhea or antibiotic-associated colitis.
Sugar Intolerance	Use with Caution	Contains sucrose; caution is needed for patients with fructose intolerance or glucose-galactose malabsorption.

Pregnancy and Breastfeeding: Fosfomycin is often considered acceptable for use in pregnant women for treating cystitis. However, as with any medication, it should only be used if clearly needed and under a doctor's guidance. Caution is also advised during breastfeeding.

Interactions with other medicines and products

This section summarizes the officially documented interactions for Фосфомицин Эспарма (Fosfomycin tromethamine), strictly based on government regulatory prescribing information.

Combinations Requiring Restriction or Avoidance

Interacting Substance	Official Regulatory Restriction
Metoclopramide (Prokinetic Agent)	Concomitant use should be avoided as it significantly lowers the serum and urinary concentrations of fosfomycin.
Medicines that Inhibit Peristalsis	Should not be given if C. difficile-associated diarrhea occurs following antibiotic use.

⏱ Timing and Pharmacokinetic Effects

Food intake may delay the absorption of this medicine, resulting in a slight decrease in peak plasma and urinary concentrations. To mitigate this effect, it is officially recommended to take Фосфомицин Эспарма on an empty stomach or approximately two to three hours after a meal.

Other Documented Interaction Notes

Substance/Class	Official Interaction Statement
Oral Anticoagulants (e.g., Warfarin)	Antibiotic therapy, in general, has been associated with an increase in oral anticoagulant activity.
Cimetidine (H2-blocker)	Co-administration has been documented to have no effect on the pharmacokinetics of fosfomycin.

Official interaction studies for this product have been performed only in adults. Reduced clearance of the drug is documented in patients with renal impairment.

How Фосфомицин Эспарма Works

Фосфомицин Эспарма exerts its action through the active ingredient Fosfomycin, which is a highly selective irreversible inhibitor of the bacterial enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase (MurA). This enzyme catalyzes the first crucial committed step in the synthesis of the bacterial cell wall component, peptidoglycan.

Fosfomycin achieves deactivation by mimicking the enzyme's natural substrate, phosphoenolpyruvate. It utilizes its unique epoxide ring structure to form a permanent covalent bond with a cysteine residue in the MurA active site, resulting in the enzyme’s functional shutdown.

This molecular block immediately halts the intracellular production of necessary peptidoglycan precursors. The resulting failure to construct or maintain the cell wall causes the bacterial cell to be unable to withstand its internal osmotic pressure. This leads to rapid cell lysis (rupture) and cell death, which is the fundamental bactericidal physiological effect of the drug.

The use of Фосфомицин Эспарма is governed by a precise, standardized regimen defined for the oral solution form. The granules are designated for oral administration and the main usage pattern for acute uncomplicated cystitis is a single 3 g dose of fosfomycin tromethamine. This defines the treatment course as a short-term, one-time administration, with no scheduled follow-up doses required for the immediate episode.

---

Administration Protocol

The preparation steps are critical for proper administration. The contents of the single-dose sachet must be fully dissolved in three to four ounces of cold water and must be consumed immediately after preparation. It is specified that the medicine must be taken on an empty stomach, which typically means two to three hours before or after a meal, to ensure optimal uptake of the active compound. The dose is often taken at bedtime following the emptying of the bladder.

---

Dosing for Specific Populations

The standard 3 g single-dose regimen is also used for adolescent females aged 12 years and older, and generally no dosage adjustment is necessary for older adults. However, it is noted that the use of oral fosfomycin is not recommended in patients with severe renal impairment, specifically those with a creatinine clearance below 10 mL/min. For specific prophylactic uses, the regimen may consist of two 3 g doses separated by 24 hours.

Research Evidence / Overview of Studies for Фосфомицин Эспарма

Evidence for Use in Uncomplicated Urinary Tract Infections (uUTI) in Women

The research exploring Фосфомицин Эспарма was studied for uncomplicated urinary tract infections (UTIs), with evidence primarily coming from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to examine outcomes such as measurements of microbiological clearance (whether the bacteria were eliminated from the urine) and patient-reported outcomes describing perceived discomfort related to UTI symptoms (like painful or frequent urination) during the study period.

Research has primarily monitored Фосфомицин Эспарма in adult non-pregnant women presenting with acute, uncomplicated UTI. Researchers typically followed up with these patients for a short period, often 7 to 14 days, to monitor how symptoms evolved and to check for microbiological status. Research highlights changes measured during this study period for the group of patients who were observed.

Comparing Фосфомицин Эспарма to Other Treatments and Placebo

Studies have explored how the measurements taken for Фосфомицин Эспарма compare to those of other antibiotics commonly used to treat uncomplicated UTIs, such as nitrofurantoin and certain cephalosporins, or, in some cases, against an inactive substance (placebo). These comparisons are part of studies focused on episodes where symptoms may vary in intensity and where microbiological clearance is monitored.

Some systematic reviews report that in the observed studies, the findings describe patterns observed in the populations when measured against other antibiotics. These studies monitored both symptom outcomes and microbiological status. It is important to understand that study results reflect the specific conditions under which they were conducted, and findings were sometimes mixed due to different study designs and the various comparator drugs used.

Evidence in Special Populations and Specific Groups

Research has also been conducted for Фосфомицин Эспарма in certain special populations. For example, some studies have evaluated its use in pregnant women who had asymptomatic bacteriuria (ASB), where studies examined the measurement of microbiological clearance of bacteria. Data for certain groups remain insufficient, especially concerning Фосфомицин Эспарма in older adults (geriatric patients) or in individuals with certain comorbid health conditions.

Durability and Long-Term Follow-up of Studies

Most of the core evidence for uncomplicated UTIs focuses on the immediate, short-term outcomes within a few weeks of treatment. Follow-up durations were limited in many primary trials. Certainty appears low because long-term effects are not well characterized, and follow-up durations were limited in the main comparative trials.

What Remains Uncertain: Evidence Gaps and Limitations

The existing evidence contributes to understanding symptom patterns but also highlights areas where research is still ongoing. Long-term effects are not well characterized because follow-up durations were limited in the main comparative trials. Furthermore, data for certain groups remain insufficient, particularly for patients with conditions marked by functional limitations. Research provides context but does not determine whether an individual will respond similarly.

Common questions about Фосфомицин Эспарма (FAQ)

Q: Does it make you sleepy or drowsy?

Official regulatory information indicates that side effects like somnolence (sleepiness or drowsiness) and dizziness have been reported. These effects are classified as very common reactions associated with this medication. Awareness of this potential reaction is often mentioned in patient resources, given its relevance to daily activities.

Q: Is it safe to drink alcohol with this medication?

Regulatory documents advise caution regarding the consumption of alcohol while taking this medication. Alcohol may increase the risk or severity of central nervous system (CNS) side effects already caused by the drug, such as dizziness, sleepiness, and difficulties with concentration. The official product information contains specific recommendations regarding co-use with alcohol.

Q: Can children 2 years old use it?

The approved uses for this medicine, according to official labeling, are generally restricted to adjunctive therapy for partial-onset seizures in children within a specific age range. The use of this drug for pain conditions, or for other indications, may not be approved for a child of 2 years old in all regions. Reference to the official label provides the most accurate information on approved age groups and indications.

Q: What is the proper way to store the capsules?

According to the official product information, the capsules are generally required to be stored at room temperature, which is typically defined as below 25°C or 30°C, depending on the region. The medicine is generally required to be kept in a dry place, protected from both direct light and moisture, to help maintain its stability.

Q: What if I miss a dose?

Official patient instructions commonly state that if a dose is missed by only a few hours, it may be taken as soon as it is remembered. However, if it is already close to the time of the next scheduled dose, the missed dose is generally skipped entirely, and the schedule is resumed with the next dose. Labeling cautions against taking a double dose to compensate for a missed one.

How to Store and Dispose of Fosfomycin Trometamol (Фосфомицин Эспарма)

Official regulatory documents define specific requirements for the storage, protection, and disposal of this medicine, supplied as granules in a single-dose sachet.

Storage Requirements

• Original Packaging: Keep the sachet in its original carton and the carton tightly closed to protect the contents from environmental exposure.
• Environment: Store the medicine in a cool, dry place, protected from both heat and direct sunlight.
• Child Safety: It must be stored out of the sight and reach of children at all times.
• Handling Stability: Once the granules are dissolved in water, the resulting solution is stable at room temperature for 24 hours; however, it is intended to be taken immediately after preparation.

Disposal Instructions

• Unused Medicine: Do not dispose of this medicine in household trash or by flushing it down a toilet or drain.
• Proper Disposal: Unused or expired medication, or any waste material, must be disposed of in accordance with local regulatory requirements, often by returning it to a pharmacy take-back program.